SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is seeing a significant surge in trading volume and price following the FDA approval of Yartemlea, its first-in-class therapy for a severe transplant-associated complication. The community is actively debating the stock's substantial undervaluation, fueled by its pipeline validation, a major licensing deal with Novo Nordisk, and potential for a short squeeze. Many foresee considerable upside, with discussions circling around valuations far exceeding current levels, while some also acknowledge concerns about possible dilution.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

The Compound (COMP) token is trending amidst a highly polarized community debate regarding its financial outlook and future direction. A key catalyst is the contentious discussion surrounding the protocol's treasury health, with some users highlighting concerns about potential depletion and low token fair value, while others express strong bullish conviction for an imminent supply shock from reaching its maximum circulating supply and potential buybacks. This internal struggle is further complicated by ongoing governance challenges and comparisons to competitor AAVE, intensifying the debate over Compound's long-term viability and immediate price trajectory.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is trending significantly following the announcement that Sanofi is acquiring the company for $15.50 per share, a move set to enhance Sanofi's adult immunization portfolio with Dynavax's key vaccine assets. The community is buzzing with discussions about the offer's fairness, with many long-term shareholders expressing frustration over the valuation compared to the stock's historical performance, while others celebrate the substantial immediate gains. This development underscores the continued strategic consolidations within the biotech vaccine sector.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos (ATOM) is trending as its community actively works on a significant tokenomics redesign to shift from inflationary rewards to a revenue-based model, aiming to enhance value accrual and mitigate sell pressure. This move is a major talking point, with some users hopeful for long-term growth given ATOM's foundational role in interoperability and ecosystem expansion. However, others remain critical of its recent price action despite attractive staking yields, leading to an active debate about ATOM's future utility within the evolving blockchain landscape.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending after recently securing FDA approval for AQVESME, making it the sole approved treatment for alpha- or beta-thalassemia. This significant regulatory win is driving broad conversation, though community perspectives are mixed, with some noting a dip in shares and discussing the implications of a required REMS program, while analysts have raised price targets.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is trending higher following significant regulatory relief, including the OCC removing a consent order and the Fed closing a supervisory notice, alongside strong earnings that underscore its ongoing transformation. The community is actively discussing its impressive multi-year rally, driven by broader financial sector optimism and ongoing corporate buybacks, though some express caution regarding its overbought technical conditions.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos (XTZ) is gaining attention due to its Etherlink L2 receiving a fintech innovation award for a 'Uranium Tokenization Breakthrough,' showcasing its strategic pivot towards Real World Assets. This news, alongside increased staking accessibility, has ignited a fierce debate within the community, with some anticipating a significant turnaround while a vocal opposing segment views the asset as a 'sucker coin' burdened by an ever-increasing supply.

Sprott Funds Trust. - Sprott Copper Miners ETF

The Sprott Copper Miners ETF ($COPP) is trending as discussions intensify around a potential copper supercycle, driven by increasing demand for the critical metal in AI and electrification. The community is actively debating the impact of possible US import tariffs on copper prices and whether this signifies a sustained bullish trend for the commodity.

Ethereum Classic

Ethereum Classic ($ETC) is trending after briefly reaching a top spot on platform trend lists, despite widespread community frustration over its significant underperformance compared to major cryptocurrencies. Investors are actively debating whether current low prices offer a prime accumulation opportunity, with many long-term holders buying the dip and anticipating a substantial breakout during a future altcoin rally. The discussion frequently centers on its historical significance as the original Ethereum and its proof-of-work mechanism, fueling hopes for a major revaluation.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

SQD is currently a hot topic following its acquisition by Rezolve Ai, which is integrating its decentralized blockchain data platform into an AI-commerce stack to enhance AI and digital-asset payments. The community is buzzing about the upcoming Tokenomics 2.0, designed to transition SQD to sustainable, usage-driven protocol rewards tied to real data demand across AI, DeFi, and RWA. This foundational utility and strategic integration are fueling strong long-term value discussions amidst active trading.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
